Lupin inks pact with Enzene for launch of biosimilar cetuximab

31 May 2023 , 09:26 AM

Lupin announced that it has entered into a strategic agreement with Enzene Biosciences for the launch of Cetuximab in India to treat head and neck cancer.

Enzene Biosciences, based in Pune, is a subsidiary of Alkem Laboratories.

Cetuximab has received approval from the Drug Controller General of India (DCGI) for being effective in the treatment of head and neck cancer. It is the first biosimilar developed for intravenous infusion. In particular, this drug could be used to treat Squamous Cell Carcinoma of the Head and Neck (SCCHN). 

Cetuximab can be purchased in a 100mg vial. 

In 2009, Eli Lily and Merck’s Cetuximab (Erbitux) have been approved by the US Food and Drug Administration (USFDA) to cure metastatic colorectal cancer and head and neck cancer.

With a staggering annual incidence of over 100,000 new cases, head and neck cancer poses a significant public health challenge in India. This cancer affects vital areas of the head and neck, such as the oral cavity, larynx, pharynx, and sinuses.

Rajeev Sibbal, President of India Region Formulations, Lupin, expressed that “the launch of the first biosimilar Cetuximab highlights the company’s commitment towards easy access to solutions and enhancing patient outcomes.”

For feedback and suggestions, write to us at [e-mail]